Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
ABT

ABT - Abbott Laboratories Stock Price, Fair Value and News

104.05USD-0.82 (-0.78%)Delayed

Market Summary

ABT
USD104.05-0.82
Delayed
-0.78%

ABT Alerts

  • 2 major insider sales recently.

ABT Stock Price

View Fullscreen

ABT RSI Chart

ABT Valuation

Market Cap

181.0B

Price/Earnings (Trailing)

32.18

Price/Sales (Trailing)

4.49

EV/EBITDA

22.19

Price/Free Cashflow

36.77

ABT Price/Sales (Trailing)

ABT Profitability

EBT Margin

16.21%

Return on Equity

14.41%

Return on Assets

7.76%

Free Cashflow Yield

2.72%

ABT Fundamentals

ABT Revenue

Revenue (TTM)

40.3B

Rev. Growth (Yr)

2.23%

Rev. Growth (Qtr)

-2.7%

ABT Earnings

Earnings (TTM)

5.6B

Earnings Growth (Yr)

-7.44%

Earnings Growth (Qtr)

-23.46%

Breaking Down ABT Revenue

Last 7 days

-0.7%

Last 30 days

-1.8%

Last 90 days

-8.7%

Trailing 12 Months

-4.1%

How does ABT drawdown profile look like?

ABT Financial Health

Current Ratio

1.6

Debt/Equity

0.32

Debt/Cashflow

0.57

ABT Investor Care

Dividend Yield

2%

Dividend/Share (TTM)

2.08

Buy Backs (1Y)

0.12%

Diluted EPS (TTM)

3.21

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202440.3B000
202341.5B40.2B40.0B40.1B
202244.5B45.5B45.0B43.7B
202137.3B40.2B42.3B43.1B
202032.1B31.4B32.2B34.6B
201930.7B30.9B31.4B31.9B
201828.4B29.6B30.4B30.6B
201722.3B23.6B25.1B27.4B
201620.4B20.6B20.7B20.9B
201520.4B20.5B20.6B20.4B
201419.6B19.7B20.0B20.2B
201321.1B20.7B20.2B19.7B
201235.1B30.8B26.2B21.5B
201136.5B37.3B38.4B38.9B
201031.7B33.1B34.0B35.2B
200929.5B29.7B29.9B30.8B
200826.8B27.7B28.6B29.5B
200700025.9B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Abbott Laboratories

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 10, 2024
funck, jr. robert e.
sold
-1,055,820
104
-10,097
executive vice president
May 10, 2024
funck, jr. robert e.
acquired
474,559
47.00
10,097
executive vice president
May 07, 2024
earnhardt lisa d
sold
-2,428,120
106
-22,852
executive vice president
Apr 26, 2024
o'grady michael
acquired
-
-
1,866
-
Apr 26, 2024
roman michael f
acquired
-
-
1,866
-
Apr 26, 2024
babineaux-fontenot claire
acquired
-
-
1,866
-
Apr 26, 2024
mcdew darren w
acquired
-
-
1,866
-
Apr 26, 2024
blount sally e.
acquired
-
-
1,866
-
Apr 26, 2024
gonzalez patricia paola
acquired
-
-
1,866
-
Apr 26, 2024
alpern robert j
acquired
-
-
1,866
-

1–10 of 50

Which funds bought or sold ABT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 16, 2024
TANDEM CAPITAL MANAGEMENT CORP /ADV
added
0.12
122,910
3,748,490
2.13%
May 16, 2024
Pineridge Advisors LLC
reduced
-5.75
-1,188
42,817
0.01%
May 16, 2024
Brown Shipley& Co Ltd
new
-
1,045,520
1,045,520
0.33%
May 16, 2024
Creekmur Asset Management LLC
added
0.69
5,081
132,988
0.05%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-43.18
-30,096,100
42,723,500
0.01%
May 16, 2024
WealthPlan Investment Management, LLC
added
2.76
630,758
10,953,200
1.67%
May 16, 2024
Wiser Advisor Group LLC
reduced
-1.12
8,624
382,174
0.60%
May 16, 2024
First Western Trust Bank
reduced
-4.08
-70,445
7,366,930
0.34%
May 16, 2024
Dynasty Wealth Management, LLC
new
-
3,944,650
3,944,650
0.13%
May 16, 2024
FSA Wealth Management LLC
added
0.13
2,871
88,871
0.04%

1–10 of 47

Are Funds Buying or Selling ABT?

Are funds buying ABT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ABT
No. of Funds

Unveiling Abbott Laboratories's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.01%
156,444,700
SC 13G/A
Jan 26, 2024
blackrock inc.
7.7%
134,061,311
SC 13G/A
Feb 09, 2023
vanguard group inc
8.92%
155,480,794
SC 13G/A
Feb 06, 2023
blackrock inc.
8.0%
139,526,216
SC 13G/A
Feb 09, 2022
vanguard group inc
8.43%
149,152,264
SC 13G/A
Feb 01, 2022
blackrock inc.
7.8%
137,155,602
SC 13G/A
Feb 16, 2021
capital research global investors
4.9%
86,394,199
SC 13G/A
Feb 10, 2021
vanguard group inc
8.31%
147,272,920
SC 13G/A
Jan 29, 2021
blackrock inc.
7.5%
133,426,810
SC 13G/A
Feb 14, 2020
capital research global investors
6.4%
113,689,293
SC 13G/A

Recent SEC filings of Abbott Laboratories

View All Filings
Date Filed Form Type Document
May 14, 2024
4
Insider Trading
May 10, 2024
144
Notice of Insider Sale Intent
May 08, 2024
4
Insider Trading
May 07, 2024
144
Notice of Insider Sale Intent
May 02, 2024
10-Q
Quarterly Report
May 01, 2024
8-K
Current Report
Apr 30, 2024
4
Insider Trading
Apr 30, 2024
4
Insider Trading
Apr 30, 2024
4
Insider Trading
Apr 30, 2024
4
Insider Trading

Peers (Alternatives to Abbott Laboratories)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
181.0B
40.3B
-1.75% -4.07%
32.18
4.49
-2.84% -3.08%
68.3B
19.7B
1.78% -6.05%
51.24
3.46
4.82% -17.56%
20.4B
3.9B
-9.57% -7.50%
44.2
5.22
5.72% 46.72%
18.0B
14.9B
-10.73% -18.01%
6.79
1.21
2.98% 207.68%
MID-CAP
9.8B
3.5B
6.68% 24.08%
31.27
2.76
6.16% 35.06%
9.6B
12.5B
6.31% -2.51%
24.63
0.77
-0.61% -18.83%
8.4B
2.6B
1.13% -22.65%
-26.02
3.22
-6.25% -68.62%
5.9B
3.9B
-6.79% -30.12%
-62.84
1.49
0.23% 91.03%
3.4B
387.1M
0.52% 31.17%
-216.3
8.9
30.82% 65.57%
2.3B
6.6B
0.19% -5.50%
11.93
0.35
2.78% -0.87%
SMALL-CAP
1.3B
3.2B
5.94% -10.00%
-1.91
0.41
7.94% -1661.78%
376.6M
169.3M
-1.13% -2.23%
-4.9
2.23
7.49% -244.90%
241.9M
324.0M
-4.58% -37.15%
-1.26
0.75
-3.19% -337.41%
56.1M
50.5M
22.73% -73.49%
-2.46
1.11
14.25% -10.06%
1.0M
3.7M
-71.13% 32.26%
-0.09
0.28
5.77% 8.23%

Abbott Laboratories News

Latest updates
Seeking Alpha3 hours ago
Investor's Business Daily17 Apr 202407:00 am

Abbott Laboratories Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-2.7%9,96410,24110,1439,9789,74710,09110,41011,25711,89511,46810,92810,22310,45610,7018,8537,3287,7268,3148,0767,9797,535
Costs and Expenses1.4%8,5788,4618,4968,4368,2388,7878,6408,8818,9839,0908,3828,8318,3478,2697,3586,6566,9686,9256,8786,7736,796
  S&GA Expenses8.6%2,9592,7242,7232,7402,7622,9732,7312,7572,7873,0482,7672,7262,7832,5702,3022,2762,5482,4132,4402,4342,478
  R&D Expenses-2.3%684700672715654725782684697762672654654698580564578595596577672
EBITDA Margin-2.1%0.21*0.21*0.20*0.20*0.21*0.23*0.25*0.26*0.25*0.24*0.24*0.23*0.22*0.19*0.17*0.16*0.18*0.18*0.18*--
Interest Expenses-11.3%141159166159153154141132131131133134135136137134139164167168171
Income Taxes5.0%211201235261244287323334429338393159250230189-11.0089.0019114396.00-40.00
Earnings Before Taxes-20.0%1,4361,7951,6711,6361,5621,3201,7582,3522,8762,3272,4931,3482,0432,3881,4215266331,2401,1031,102632
EBT Margin-2.4%0.16*0.17*0.15*0.16*0.17*0.19*0.21*0.22*0.20*0.19*0.20*0.18*0.17*0.14*0.12*0.11*0.13*0.13*0.12*--
Net Income-23.5%1,2201,5941,4361,3751,3181,0331,4352,0182,4471,9892,1001,1891,7932,1621,2325375641,0499601,006672
Net Income Margin-2.2%0.14*0.14*0.13*0.13*0.14*0.16*0.18*0.19*0.17*0.16*0.17*0.16*0.15*0.13*0.10*0.10*0.11*0.12*0.10*--
Free Cashflow-72.5%6272,2831,3176967631,7162,3132,0311,7442,4532,2401,7152,2403,1191,5706803551,9821,547--
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-1.0%72,46773,21472,09073,35473,79474,43872,80174,20274,00721,17473,79573,26972,78520,95569,04368,77666,77718,00768,53968,42767,610
  Current Assets-1.3%22,37622,67022,66423,50524,37725,22424,84524,95623,42924,23923,49222,62721,81720,44117,39017,22115,49815,66716,11915,19514,409
    Cash Equivalents-8.9%6,2846,8966,7097,8359,1619,8829,5948,9377,6759,7999,3028,6588,0546,8384,4804,7633,3773,8604,0913,1373,022
  Inventory3.9%6,8276,5706,6506,8716,6736,1735,7345,8995,6915,1575,2615,4395,3875,0125,1525,2024,5684,3164,3924,3524,085
  Net PPE-0.5%10,10710,1549,5529,4499,2829,1628,6898,8188,9088,9598,8318,8168,8329,0298,6208,3437,9078,0387,8257,8257,626
  Goodwill-1.2%23,40023,67923,30023,30022,92722,79922,28422,74423,17923,20023,30023,50023,38423,70023,30023,10022,92723,20023,04623,32923,209
  Current Liabilities1.3%14,02113,84113,04214,35014,53015,48913,36512,39212,64713,10512,86712,61412,46211,90710,25710,95910,80810,86310,4919,0629,113
  Short Term Borrowings-----------197199199213208205204201204204201
  Long Term Debt-7.5%12,57613,59914,47714,56214,61514,52215,29716,75517,08617,29617,44617,54717,48918,52718,34918,18416,80416,66117,63918,98218,845
    LT Debt, Current86.1%2,0101,0801,0512,2842,2852,2511,1175.004.007547547557567.006.001,2901,2641,2771,2548.008.00
    LT Debt, Non Current-100.0%-13,59914,47714,56214,61514,52215,29716,75517,08617,29617,44617,54717,48918,52718,34918,18416,80416,66117,63918,98218,845
Shareholder's Equity1.1%39,04338,60337,48172.0037,01036,68635,67510879.0013541.0033,80033,56224,14531,38679.0016531,08860.0031,68623.00
  Retained Earnings1.2%38,01137,55436,92036,35535,86835,25735,11534,48733,29531,52830,37629,05328,66927,62726,26625,66925,78625,84725,44025,04524,613
Accumulated Depreciation1.4%11,94811,77911,55911,47711,32311,05010,61710,64010,61310,40510,35110,2589,8659,7649,3529,0318,8008,7618,5188,5068,279
Shares Outstanding0.0%1,7401,7401,7401,7401,7421,7531,7561,7581,7621,7751,7751,7791,7771,7731,7741,7711,7691,7681,768--
Minority Interest4.0%233224213230222219209226230222216229226219209220209213202208204
Float----185,171---186,105---200,631---157,957---144,957-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-66.3%1,0253,0381,8771,2031,1432,3262,7802,4102,0653,0672,7012,1282,6373,7982,0661,3227152,4161,9481,060712
  Share Based Compensation166.7%30411411713228111512314230510611413228898.0010011523385.0094.00114226
Cashflow From Investing48.4%-425-824-634-1,213-462-632-484-264-360-671-651-264-422-731-472-619-393-489-432-498-396
Cashflow From Financing42.7%-1,176-2,052-2,340-1,289-1,410-1,457-1,543-813-3,823-1,886-1,377-1,264-967-787-1,915658-735-2,185-513-449-1,142
  Dividend Payments-100.0%-888888890890823826828832798801803800641639642638568569568565
  Buy Backs-12.7%2262592.004265406857985.002,3079745794712751612.004.002364961.004.00217
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

ABT Income Statement

2024-03-31
Condensed Consolidated Statement of Earnings (Unaudited) - USD ($)
shares in Thousands, $ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Net sales$ 9,964$ 9,747
Cost of products sold, excluding amortization of intangible assets4,4634,331
Amortization of intangible assets472491
Research and development684654
Selling, general and administrative2,9592,762
Total operating cost and expenses8,5788,238
Operating earnings1,3861,509
Interest expense141153
Interest (income)(80)(101)
Net foreign exchange (gain) loss06
Other (income) expense, net(111)(111)
Earnings before taxes1,4361,562
Taxes on earnings211244
Net Earnings$ 1,225$ 1,318
Basic Earnings Per Common Share (in dollars per share)$ 0.70$ 0.75
Diluted Earnings Per Common Share (in dollars per share)$ 0.70$ 0.75
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)1,740,2031,741,738
Dilutive Common Stock Options (in shares)9,4499,977
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)1,749,6521,751,715
Outstanding Common Stock Options Having No Dilutive Effect (in shares)6,8927,332

ABT Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheet (Unaudited) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current Assets:  
Cash and cash equivalents$ 6,284$ 6,896
Short-term investments367383
Trade receivables, less allowances of $439 in 2024 and $444 in 20236,6056,565
Inventories:  
Finished products4,0633,946
Work in process881807
Materials1,8831,817
Total inventories6,8276,570
Prepaid expenses and other receivables2,2932,256
Total Current Assets22,37622,670
Investments818799
Property and equipment, at cost22,05521,933
Less: accumulated depreciation and amortization11,94811,779
Net property and equipment10,10710,154
Intangible assets, net of amortization8,2968,815
Goodwill23,38323,679
Deferred income taxes and other assets7,4877,097
Total Assets72,46773,214
Current Liabilities:  
Trade accounts payable4,1784,295
Salaries, wages and commissions1,0921,597
Other accrued liabilities5,2205,422
Dividends payable959955
Income taxes payable562492
Current portion of long-term debt2,0101,080
Total Current Liabilities14,02113,841
Long-term debt12,57613,599
Post-employment obligations, deferred income taxes and other long-term liabilities6,8276,947
Commitments and Contingencies
Shareholders’ Investment:  
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued00
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2024: 1,989,789,999; 2023: 1,987,883,85224,72624,869
Common shares held in treasury, at cost — Shares: 2024: 250,155,515; 2023: 253,807,494(15,761)(15,981)
Earnings employed in the business38,01137,554
Accumulated other comprehensive income (loss)(8,166)(7,839)
Total Abbott Shareholders’ Investment38,81038,603
Noncontrolling Interests in Subsidiaries233224
Total Shareholders’ Investment39,04338,827
Total Liabilities and Shareholders' Investment$ 72,467$ 73,214
ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
 CEO
 WEBSITEabbott.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES65535

Abbott Laboratories Frequently Asked Questions


What is the ticker symbol for Abbott Laboratories? What does ABT stand for in stocks?

ABT is the stock ticker symbol of Abbott Laboratories. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Abbott Laboratories (ABT)?

As of Fri May 17 2024, market cap of Abbott Laboratories is 181.01 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABT stock?

You can check ABT's fair value in chart for subscribers.

What is the fair value of ABT stock?

You can check ABT's fair value in chart for subscribers. The fair value of Abbott Laboratories is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Abbott Laboratories is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Abbott Laboratories a good stock to buy?

The fair value guage provides a quick view whether ABT is over valued or under valued. Whether Abbott Laboratories is cheap or expensive depends on the assumptions which impact Abbott Laboratories's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABT.

What is Abbott Laboratories's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ABT's PE ratio (Price to Earnings) is 32.18 and Price to Sales (PS) ratio is 4.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Abbott Laboratories's stock?

In the past 10 years, Abbott Laboratories has provided 0.12 (multiply by 100 for percentage) rate of return.